Trexquant Investment LP Has $4.39 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Trexquant Investment LP decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 47.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 52,585 shares of the biopharmaceutical company's stock after selling 46,964 shares during the quarter. Trexquant Investment LP's holdings in Intra-Cellular Therapies were worth $4,392,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 240 shares during the period. Venturi Wealth Management LLC bought a new position in Intra-Cellular Therapies in the fourth quarter worth $96,000. Wilmington Savings Fund Society FSB acquired a new stake in Intra-Cellular Therapies during the third quarter worth $97,000. Quarry LP increased its holdings in Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after buying an additional 1,300 shares during the period. Finally, Barlow Wealth Partners Inc. acquired a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at $184,000. Institutional investors and hedge funds own 92.33% of the company's stock.

Intra-Cellular Therapies Price Performance

ITCI stock remained flat at $131.87 during midday trading on Thursday. The stock has a fifty day moving average of $130.10 and a two-hundred day moving average of $103.37. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.98. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. As a group, analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ITCI shares. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Canaccord Genuity Group cut Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Cantor Fitzgerald restated a "neutral" rating and issued a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Finally, Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies has a consensus rating of "Hold" and a consensus target price of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.